Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study

•Limited clinical data are available to guide treatment decisions after ICI failure in patients with NSCLC.•VARGADO cohort B included patients with adenocarcinoma NSCLC after failure of chemotherapy and ICI.•Nintedanib plus docetaxel showed real-world efficacy after failure of prior ICIs.•Median PFS and overall survival were 6.4 and 12.1 months; 1-year overall survival rate was 52% and DCR was 86%.•74% of patients reported treatment-related adverse events, with diarrhoea being the most common.